A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD

N/AEnrolling By InvitationNCT07093528

Mayo Clinic25 enrolled

Overview

To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Heart Failure With Preserved Ejection Fraction Coronary Microvascular Dysfunction

Interventions

Cardiovascular Magnetic Resonance (CMR)DIAGNOSTIC_TEST

Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 * Enrollment in main CS-reducer HFPEF study IRB# 25-002292 Exclusion Criteria: * Metal implants that are not suitable for MRI * Inability or unwillingness of individual to give written informed consent.

Locations (1)

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Change in endocardial:epicardial perfusion ratio

Endocardial:Epicardial Perfusion Ratio is a measure of myocardial blood flow and will be determined by Cardiovascular magnetic resonance (CMR)

Time frame: Baseline, 6 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.